Northwest Biotherapeutics (NWBO) Return on Capital Employed (2011 - 2026)

Northwest Biotherapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 2323.69% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 220200.0% year-over-year to 2323.69% in Q1 2026; TTM through Mar 2026 was 2323.69%, a 220200.0% increase from a year earlier, with the FY2025 full-year figure at 158.96%, down 334.0% from the prior year.
• Return on Capital Employed improved to 2323.69% in Q1 2026 per NWBO's latest filing, from 167.59% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 2323.69% in Q1 2026 and bottomed at 48.01% in Q1 2022.
• The 5-year median for Return on Capital Employed is 167.59% (2025), against an average of 333.06%.
• Across the five-year window, Return on Capital Employed slumped 42702 bps in 2024 and soared 220200 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 70.87% in 2022, then jumped by 404 bps to 357.53% in 2023, then slumped by 54 bps to 165.24% in 2024, then grew by 1 bps to 167.59% in 2025, then surged by 1287 bps to 2323.69% in 2026.
• Per Business Quant, the three latest NWBO Return on Capital Employed figures stand at 2323.69% (Q1 2026), 167.59% (Q4 2025), and 112.25% (Q3 2025).